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Background .The pharmacology, toxicology and pharmacokinetics of bioactive preparations 
derived from natural sources has become a flourishing field of research. However, 
researching complex extracts and natural products faces numerous challenges. More broadly 
in recent years the critique of pharmacological research, and specifically its design, the 
methods used and reporting has intensified.  . 
Aims: This consensus document provides a perspective on what constitutes best practice in 
pharmacological research on bioactive preparations derived from natural sources, providing a 
perspective of what the leading specialist journals in the field consider as the core 
characteristics of good research. 
Approach (’Methods’). The editors in chief of seven journals developed this best practice 
statement in an iterative process. A first draft of the guidelines (prepared by MH) was then 
discussed and amended by the other authors.  
Outcomes. Core to this contribution is a table which provides detailed advice including 
simple points like a use of appropriate controls and the full taxonomic validity of the material 
under investigation (see also below), to the relevance of the model for the question being 
researched (e.g. can specific in silico or in vitro models really say s.th. about the species anti-
inflammatory activity?). Therefore, obviously, researchers must pay detailed attention to 
reporting and discussing such studies. This information must be discussed critically (as much 
as it is possible based on the published papers) in terms of their scientific quality and validity. 
While these points are obvious, as editors we are aware that they are often not properly 
implemented.  
Conclusion. We call for an approach which incorporates a careful design, meticulous 
execution and a detailed reporting of studies focusing on the pharmacology / bioactivity of 
bioactive preparations. Clearly testable research questions must be developed and 
investigated experimentally. As the founder of pharmacology Claude Bernard put it already 
in 1865: ‘…. either the experimenter’s hypothesis will be disproved or it will be proved by 






‘Experimenters must doubt, avoid fixed ideas, and always keep their 
freedom of mind’ [Bernard 1957: 35 (French original 1865)] 
The critique of research on pharmacology, toxicology and pharmacokinetics of bioactive 
substances has intensified over the years. Challenges to these approaches are numerous and in 
2005 Ionides claimed “Simulations show that for most study designs and settings, it is more 
likely for a research claim to be false than true.” In other words “It can be proven that most 
claimed research findings are false.” (Ionides 2005) One cannot be more direct in stating the 
problem of reproducibility in the designing, analysing and reporting research. Moreover, for 
many current scientific fields, claimed research findings may often be simply accurate 
measures of the prevailing bias.” (Ioannidis 2005, 0696). Think, for example, of a period of 
around 30 years, when it was thought that the human diploid chromosome number was 48, 
and essentially all work conducted by geneticists was considered flawed, until the correct 
number of 46 was reported in 1956 (cf. Harper 2006).  
In this best practice statement we look specifically at the challenges faced in the area of 
natural products research and medicinal plant preparations with respect to their 
pharmacological study. The huge field of pharmacology is no exception to this lack of 
reproducibility and this has resulted in pharmacological journals publishing a range of best 
practice guidelines or consensus documents (e.g., Mullane et al. 2015). Our observations aim 
to help researchers develop and report their pharmacological findings and to remain 
cognizant of the challenges in the complex workflow which defines natural product research. 
Toxicological and pharmacokinetic studies are not covered here. 
Focusing on medicinal plant research, several added challenges need to be recognised. First 
and foremost, the field is unique in tackling pharmacological and biological activities of 
complex mixtures of active and inactive natural products. If we want the use of medicinal 
plants and later as regulated herbal medicinal products (rational phytotherapy) to be a 
science-based medical practice, “controlled clinical trials or in rigorous biomedical studies” 
(Heinrich 2013) are needed. The interpretation and acceptance of such evidence for 
phytotherapeutic practices varies. This is often driven by regulatory agencies, which require 
different types and levels of evidence, but in some countries/regions products are accepted as 
regulated (medical) substances, while in others they remain, in essence, unregulated or 
accepted as “traditionally used preparations” (Bodecker et al. 2005; WHO 2005). As editors, 
it is our broader aim to support the use of nature-derived products as evidence-based 
medicines whether they are used as extracts (phytotherapy/ethnopharmacology) or as pure 
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and defined natural products. Equally important, there is a long-standing consensus that the 
interface between food and medicines is fluid and culturally defined. For pharmacological 
research, this poses particular challenges in deciding whether an intervention or 
pharmacological experiment actually focuses on a potential use as a healthy food (e.g., 
nutraceutical) or a medicine.  
As editors, we have seen a large number of manuscripts and, while all the above challenges 
provide a crucial wider context, we also have seen numerous examples of good and bad 
practice in designing, analysing and reporting pharmacological studies. The aim of this review 
is to provide guidelines for best practice encouraging authors to ascertain that they follow 
these recommendations. These are not rigorously defined minimal standards, but criteria to be 
met in order to publish in Fitoterapia, Frontiers in Pharmacology (Sect. 
Ethnopharmacology), Pharmaceutical Biology, Phytomedicine, Phytotherapy Research, 
Planta Medica and Journal of Ethnopharmacology, all being leading journals in the field.  
Thus, this paper is a consensus statement by the editors-in-chief of these main journals in the 
field of medicinal plant research, ethnopharmacology and natural product research. It cannot 
be a specific set of requirements; rather, it is a set of guidelines which will hopefully help 
researchers to develop more robust pharmacological experiments and, thus, to improve the 
quality of the studies submitted to any journal in the field. Each of the journals undersigning 
this consensus statement has its own specific requirements and the guidelines published here 
do not replace nor necessarily include these requirements. Instead, the consensus document 
is intended as a guide to develop best practice from an early stage, irrespective of any plans 
for a publication in a specific journal at the end of the study. Therefore, we also hope that it 
will be adopted more widely in the field 
 
Common concerns in publishing results in the area of phytopharmacology 
From a methodological standpoint, research on bioactive natural products is more challenging 
than studies performed with synthetic compounds. Nature does not intentionally produce 
secondary metabolites for human benefit. Rather, the metabolites serve some function for the 
producers, and the complexity of extracts poses unique challenges.  
In Table 1, key areas are covered which require attention in designing, analysing and 
reporting research. Broadly speaking, the challenges we as editors have seen, include: 
- The suitability of specific and accurate models for understanding and predicting an 
effect (cf. the recommendations by Butterweck and Nahrstedt 2012) 
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- Ambiguities about the composition of the preparation under study (i.e., the need for a 
full botanical/biological definition of the starting material and for adequate 
characterisation of the extract used) 
- Lack of evidence for novelty of the research  
- Predictability of the results. Certain types of bioactivity are class-related rather than 
associated with a specific molecular construct. Thus, the presence of oxygenated 
functions on aromatic rings results in positive response with chemical (e.g., ORAC 
and DPPH) and cellular (protection from oxidative degradation of biomolecules) 
assays. These are chemical reactions that cannot be judged as biologically relevant 
without ancillary testing 
- The specificity of an effect or the lack of such specific effects. It is now a well-known 
concern that a wide range of compounds are active in a large number of mostly in 
vitro, but also in vivo models, which, however, cannot be translated into evidence for 
therapeutic benefits 
- The ethical basis of animal experiments is often not evaluated carefully or only 
limited information on such an assessment is provided. While in vivo studies are 
generally approved by a relevant ethics committee, such studies are often poorly 
justified scientifically (Is this study really needed?).  
- The relevance, limitations and misinterpretation of statistical significance (P values) 
(e.g., Mullane et al. 2015, Ioannidis 2005, cf. also Amrehein et al 2019). We consider 
statistical significance necessary but pharmacological and physiological relevance are 
of utmost importance (cf. Comment 2019) 
- Limited or no justification for animal studies. In vivo research (and clinical studies) 
are often not justified in the context of their therapeutic relevance nor are they based 
on high quality in vitro data. Similarly, in vitro studies have been shown to pose 
numerous problems with the main concern often being the reporting of irrelevant 
findings. 
 
Drugability factors such as solubility, stability, and reactivity, normally addressed in the 
planning of synthetic libraries, are often largely unresolved with libraries of natural products. 
Compounds from isolation programs are often insoluble, unstable, or embellished with 
structural elements alien to synthetic drugs, such as the ene-dyine anticancer agents. Such 
challenges need to be overcome. Pan-assay interference compounds, or PAINS have become 
a major point for discussion in drug discovery (Baell and Walters 2014). Such compounds 
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interact with multiple targets and thus are ‘promiscuous’ (Hu and Bajorath, 2013). They are 
of particular concern in enzyme-based assays and we recognise this challenge, but many of 
the studies which reach the journals brought together here use in vivo and/or cell-based assays 
which are less likely to be affected. However, the specificity of action remains an important 
point one needs to consider in phytoharmacology.  
 
Numerous other problems have been identified in the context of pharmacological research. 
While ‘experiments must doubt’, we can avoid common mistakes and develop a strategy 
which is best suited for research in this field today.  
We are not addressing in detail the food uses of plants nor at the assessment of a species’ 
toxicity. Nor can chemical or botanical aspects be covered in great detail, but for the latter, 
clear guidelines are available (Rivera et al 2014).  
 
Approach and methods 
This review is based on an iterative process between the authors. Following the initial idea 
(MH), a draft checklist was developed which was modified over a range of iterations. While 
we did not follow a formal Delphi process, during several rounds, responses were aggregated 
and shared with the group after each round. Individual editors added specific concerns 
commonly found in the journals they are representing and all then agreed whether this should 
be seen as a common requirement or not.  
Pharmacology and natural product research – common challenges and 
standards of research 
All journals involved in this consensus project publish papers which contribute to an 
understanding of the pharmacological effects of complex mixtures and of metabolites derived 
from them. In the following, we provide a brief overview on the scope of each of these 
journals:  
 Fitoterapia (https://www.journals.elsevier.com/fitoterapia) publishes mainly 
molecularly-oriented manuscripts on natural products (novel structures or synthesis, 
identification of mechanisms of action and targets, molecular editing of natural 
products, and structure-activity relationships). It started to publish research articles in 
1930 (predecessor Estratti fluidi titolati), but until ca. 1935 these were occasional 
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publications. The journal publishes contributions in seven major areas: 
1. Characterization of active ingredients of medicinal plants 
2. Development of standardization method for bioactive plant extracts and natural 
products 
3. Identification of bioactivity in plant extracts 
4. Identification of targets and mechanism of activity of plant extracts 
5. Production and genomic characterization of medicinal plants biomass 
6. Chemistry and biochemistry of bioactive natural products of plant origin 
7. Critical reviews of the historical, clinical and legal status of medicinal plants, and 
accounts on topical issues. 
 Frontiers in Pharmacology – section Ethnopharmacology 
(https://www.frontiersin.org/journals/pharmacology/sections/ethnopharmacology#) 
started publishing in 2010 and ‘is a worldwide, open access platform for bioscientific, 
clinical and sociocultural research on medicinal and food plants as well as other 
natural substances used throughout the world. This multidisciplinary approach is an 
essential basis for the use of these resources in tomorrow’s medicines. Neglected 
diseases, including such common ones as vector-borne ones, diarrhea or tuberculosis 
are still commonly treated with herbal medicines. … A core challenge in 
pharmacology is the scientific study of the complex products derived from such 
traditions. Extracts obtained from plants, fungi or animals pose some unique 
challenges: they are multicomponent mixtures of active, partially active and inactive 
substances and the activity is often not on a single target.’ (Heinrich 2010) 
 ‘The Journal of Ethnopharmacology (https://www.journals.elsevier.com/journal-of-
ethnopharmacology) was started in 1989 and publishes original articles concerned 
with the observation and experimental investigation of the biological activities of 
plant and animal substances used in traditional medicines of past and present cultures. 
The journal particularly welcomes interdisciplinary papers with an 
ethnopharmacological, an ethnobotanical or an ethnochemical approach to the study 
of indigenous drugs. Reports of anthropological and ethnobotanical field studies fall 
within the journal's scope. Studies involving pharmacological and toxicological 
mechanisms of action are especially welcome.’ 
 Pharmaceutical Biology (https://www.tandfonline.com/loi/iphb20) was started in 
1961 (as the ‘Quarterly Journal of Crude Drug Research’) and is an open access, peer 
reviewed journal, publishing manuscripts describing high-level research on natural 
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medicines, as well as biologically active natural products or their derivatives. 
Investigations on complex traditional medicine formulas are also welcome. Topics 
may generally encompass any facet of natural product research related to 
pharmaceutical biology. Papers dealing with agents or topics related to natural 
product drugs are also appropriate (e.g., semi-synthetic derivatives). The primary 
criteria for acceptance and publication are scientific rigor and potential to advance the 
field. 
Some more specific examples of manuscripts falling within the scope of the journal 
follow: 
 -Discovery of novel bioactive chemicals from natural sources (including herbal 
medicines, marine organisms, and microorganisms) 
 -Structural modification of bioactive natural products and structure-activity 
relationship studies 
 -Quality control of herbal medicines 
 -Pharmacology, pharmacokinetics, toxicity, and clinical studies of natural products 
and herbal medicines 
 -Biosynthesis and biocatalysis of natural products 
 -For studies on complex herbal extracts, it is mandatory to characterize their chemical 
composition, for instance, HPLC fingerprinting analysis or quantization of major 
compounds.  
Since 1994, Phytomedicine (https://www.journals.elsevier.com/phytomedicine) covers a 
broad range of topics, including pharmacological, molecular biological, toxicological, 
pharmacokinetic and clinical studies. It is is primarily a therapy-oriented journal and 
publishes innovative studies on efficacy, safety, quality and mechanisms of action of 
specified plant extracts, and their isolated constituents. Phytomedicine aims to facilitate 
the integration of phytotherapy-related products into conventional medicine. Covered 
topics include clinical pharmacology and toxicology, neurological disorders, age-
associated disorders, neuropharmacology, endocrine pharmacology, metabolic syndrome 
and obesity, cancer, immunopharmacology and inflammation, infectious diseases, 
pulmonary, gastrointestinal, cardiovascular and urogenital diseases, systems biology, 
safety assessment, pre-clinical toxicology, and drug interactions, pharmacokinetic studies, 
standardization of herbal preparations, legislation of botanicals, and invited reviews. 
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 Since 1987 Phytotherapy Research 
(https://onlinelibrary.wiley.com/page/journal/10991573/homepage/productinformatio
n.html) covers all aspects of experimental and clinical pharmacology of plant-derived 
products. Mechanistic studies on isolated metabolites as well as studies on humans 
(from case reports to randomized clinical trials), systematic reviews and meta-analysis 
of clinical trials are particularly welcome. The journal does not publish agricultural, 
phytochemical, structure elucidation, quality control or botanical identification papers 
unless they have a pharmacological focus and relevance. 
 Planta Medica – Journal for Medicinal Plant and Natural Product Research 
(https://www.thieme.de/de/planta-medica/aims-and-scope-120123.htm) publishes 
original research on natural products (including those from marine organisms, fungi 
as well as micro-organisms) and medicinal plants as well as review articles. It covers 
the following areas of medicinal plant and natural product research: biological and 
pharmacological activities; natural product chemistry and analytical studies; 
pharmacokinetic investigations; and formulation and delivery systems of natural 
products. 
 
Practical approaches to developing projects and reporting the outcomes 
Development 
As scientists and editors we are often surprised how little effort goes – prior to conducting the 
experiments – into a thorough assessment of the available literature on a topic. In case of 
medicinal plant/natural product research, this include the source organism or compound 
under study as well as the methods and the wider approach. In general, one would expect that 
a paper to be submitted reports a substantive body of phytopharmacological research and it 
must be an independent addition to the literature. Based on this, well-defined objectives of 
research (i.e., a series of clear research questions) or a testable hypothesis should be 
developed. Detailed planning and design are incorporated into Table 1; the underlying 





This consensus document cannot be about the specifics of experimental approaches, but all 
investigators must give consideration to developing the pharmacological element in a project 
(for a detailed checklist see Table 1). Specifically, this ranges from fundamental points such 
as including appropriate (positive and negative) controls and ascertaining the full taxonomic 
validity of the material under investigation (Rivera et al. 2014), to ascertaining that the 
models used are suitable for the questions being researched (e.g., can specific in silico or in 
vitro models really correlate with the pharmacological activity of the compound or extract?). 
The type of extract must be defined in sufficient detail and the specific requirements for this 
vary from journal to journal.  
There are numerous challenges in conducting experiments. As pointed out recently, for 
example, triplicate experiments may not provide a sufficient data set for calculations of 
significance (Amrehein et al 2019) and a careful evaluation of the results is needed. Core 
questions include (cf. Table 1): 
 Was the available information before starting the experiments sufficient to set up my 
hypothesis?  
 Was the preparation of the extract done in such a way that potentially active 
compounds were extracted and remained stable (see the famous example of the 
identification of artemisinin by Youyou Tu, 2017) 
 Are the identified biomarkers really therapeutically relevant or are these analytical 
(quality) markers? 
 Were the right controls included? 
 Are predictions in my experiment really feasible and testable (Right model, right 
concentration)?  
 Was there at least one clear prediction based on a dependent variable?  
 Often, a local/traditional use is presented as the very basis on which a study is 
designed. However, what then proceeds is so far removed from the traditional 
practice, e.g., can the inhalation of a medicinal smoke to treat respiratory infections be 
represented in the laboratory by the preparation of a methanolic extract of the plant 
material, surely not. Researchers in the field of evidence-based ethnopharmacology 
need to ask, does my experimental design mimic, as closely as possible, the 
local/traditional use and preparation under investigation?  
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From the point of editors, publication of negative results flanked by solid supporting positive 
data is always welcome and will be published. This is indeed the avenue to knowledge, 
preventing the redoing of scientific experiments, which are inconclusive or ‘negative’. Of 
utmost importance is the fact that a logical question is being asked in a rational manner, and a 
negative response to the question can be as important as a positive response, as long as the 
answer is credible and definitive. 
 
Reporting 
In the most simplistic way, we all need to remember that data need to be reported 
comprehensively but at the same time succinctly (see Table 1). A common problem 
encountered in reporting is a lack of a critical assessment of the data. Coming back to Claude 
Bernard, ‘Never make experiments to confirm one’s ideas, but simply to evaluate them’ (Il ne 
fallait jamais faire des expériences pour confirmer ses idées, mais simplement pour les 
contrôler; emphasis MH). In other words, science, in general, including 
phytopharmacological research, aims at demonstrating that a certain preparation is active, but 
it is the task of researchers to assess whether a pharmacological effect can be found or not. 
What happens if data do not support my hypothesis? It may but it does not prove that the 
hypothesis is wrong. It may show that the pharmacological model is too complex and 
additional experiments need to be conducted. Disproving can very well mean important 
information is available to share. Therefore, if ‘no’ activity is found in a certain model and at 
a certain concentration, this is equally relevant. While such a statement may sound trivial, we 
have seen many examples now where researchers try to prove that a certain (local or 
traditional) medicine is active, but use a scientific approach that is fundamentally flawed.  
It needs to be remembered that the results obtained are pre-determined and depend on the 
methods used. For example, for many years antimicrobial activity was determined through 
biocidal and biostatic assays.  If a plant extract was not active in these assays it was discarded 
and labelled as not being antimicrobial active. It has now emerged that many botanicals may 
rather exert antimicrobial activity through a different mechanism of action, e.g., interfering 
with bacterial quorum sensing which would not be detected in assays acutely focusing on a 




We cannot enter into the large area of research ethics, but simply want to draw attention to 
the need for compliance with a large range of ethical standards including those for access to 
biological materials (Heinrich and Hesketh 2018), the conduct of research (including 
authorship; justification of animal experiments) and its reporting (publishing ethics, see the 
COPE Guidelines - 
http://publicationethics.org/files/International%20standards_authors_for%20website_11_Nov
_2011.pdf and https://www.elsevier.com/authors/journal-authors/policies-and-ethics / 
https://www.frontiersin.org/about/author-guidelines / https://www.thieme.de/de/zeitschrift-
palliativmedizin/publication-ethics-140346.htm / 
https://authorservices.wiley.com/editors/ethical-guidelines/index.html ).  
 
Conclusions 
If ‘[e]xperimenters must doubt’, as we had highlighted in the introduction using Claude 
Bernard’s classical work, with this consensus document we want to ascertain that 
experimenters (researchers) understand what is needed to successfully develop, conduct and 
report research on bioactive preparations derived from natural sources. The overarching 
answer has again been given by Claude Bernard: ‘…. either the experimenter’s hypothesis 
will be disproved or it will be proved by experiment. When experiment disproves its 
preconceived ideas, the experimenter must discard or modify it.’ (Bernard 1957: 52).  
This paper provides qualitative standards for reproducibility and significance of bioactivity 
data on natural products/extracts across the most popular scientific journals used to 
disseminate such results. The driving motivation of all editors is to provide clear and 
transparent guidelines for a fair review process that meets criteria for responsible 
dissemination at a high level of good publishing practice. All editors are aware that 
contemporary research is interdisciplinary and driven by much larger datasets as compared 
with the last two decades, and with these guidelines, we want to ascertain that the standards 
in the field of phytopharmacology keep up with the more general developments in 
pharmacology. At the same time, no state-of-the-art highly sophisticated technique can 
provide meaningful and reproducible data if the fundamental requirements of research are not 




In bringing together journals with a common focus and similar opportunities as well as 
challenges our statement as editors of scientific journals in the field is novel. Previous 
generations of researchers have also been confronted with similar questions. However, it has 
become more prominent in recent years, where data acquisition and analysis seems easier, but 
also more reliant on specialists who only support the natural product scientist in an 
interdisciplinary team. Recently, there has been an unprecedented number of papers 
withdrawn or retracted from the scientific literature. Therefore, all editors must ask the 
question of accurate data handling and request precision in a rapidly changing technical and 
digital world.  
In the field of ethnopharmacology/medicinal plant research, scientists have special 
professional and social responsibilities. Data describing biological activity may reach the 
general public who use these results as a guide to treat various diseases, many of which are 
very serious. Use of excessively high doses, poorly characterised extracts, and claims for 
effects of extracts which are not commonly used, are examples of factors that may be used 
inappropriately if they are not reported and discussed adequately. Inadequate toxicological 
data may lead to harming patients. It is our responsibility to deliver new high quality and 
reproducible findings for the future benefit of patients and for the development of natural 
product research on new or known drug substances. 
In conclusion, with this statement, we want to encourage all members of the scientific 
community to embrace strategies that enable further evidence-based development of natural 
products using a rigorous scientific approach. Our job is not to fill the literature with 
meaningless and mundane reports of nebulous significance. Our goal is to assist researchers 
in disseminating findings in a continuum that moves solid scientific knowledge from the level 
of the research bench to the rest of the world. 
 
Table 1: General requirements for developing, conducting and reporting pharmacological 




Key questions Specific approaches / topics 
Developing How relevant is the Background assessment of the literature on the 
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the project botanical drug / plant in 
phytotherapy / local or 
traditional medicine / drug 
development?  
species’ use(s)/ future therapeutic potential? 
 
Include all available relevant data from available 
database that are accepted in our field. 
 
It is essential to demonstrate the novelty of the 
study. Studies which report similar activities of 
chemically similar species or extracts are not 
acceptable. 
 
What evidence is already 
available on the species 
and related taxa as well as 
on the specific extract to 
be studied?  
Assessment of the novelty of the study.  
 
For newly studied pharmacological effects and 
especially for reviews include original 
records/books in original language. Equally 
important, the relevant ecological or behavioural 
information should be included if the work is 
based on such data. 
Reporting only the total number of compounds 
provides very limited justification for a study. An 
analysis using, for example, VOS Viewer 
(http://www.vosviewer.com) or other free 
software should extract main trends and 
importance of subdata. 
In the case of multiherbal 
(complex) preparations: 
How relevant is this 
preparation or how is 
research with the product 
justified?  
Background assessment of the literature on the 
use(s) of the preparation? 
 
Justification of the study of multiherbal 
preparations (e.g., from ethnopharmacological or 
clinical perspective). 
In these preparations, some information on the 




Some indication should be provided on why the 
authors believe the work can be reproduced or 
expanded based on others obtaining an equivalent 
product. The emergence of meta-barcoding proves 
to be highly efficient in characterizing complex 
herbal formulations. 
Can the plant be sourced 
sustainably?  
Assessment of potential sourcing problems / 
sustainability concerns (a concern which is of 
particular relevance for collections from the wild 
(see also Materials and Methods on the botanical 
material). 
  
Are there any potential 
ethical aspects which need 
to be resolved prior to the 
start of the project? 
Justification of the model (in vivo), of sustainable 
sourcing (see below), compliance with 
international treatise (Nagoya etc.) and national 
regulations of sourcing and benefit sharing. The 
use of animals (incl. insects) or other organisms 
(bacteria) must be justified in the context of 
novelty of the research (see below). 





Definition of specific methods and tools including 
in vitro or in vivo approaches. 
In vivo studies: Which 
methods have the highest 
value for prediction and 
will lead to therapeutically 
relevant results?  
 
Ascertain that the baseline data are sufficiently 
robust and sound and use the 3Rs for best practice 
using animals [Refinement - improve the quality 
of scientific papers using animal experimentation 
– reduction - diminish the number of animals 
needed in animal experimentation and improve 
animal welfare, and replacement  - substitute 
animal experiments with other approaches.  
The repetitive study of similar preparations or 
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compounds has rightfully been seen as one of the 
main problems in the large-scale use of animals, 
especially in academic research, and may be the 
easiest of the three Rs to tackle.  
In case of plants used 
based on indigenous / 
traditional medical 
concepts: Can the 
traditional use be 
meaningfully represented 
in a pharmacological 
model?  
Assessment of the ‘translatability’ of traditional 
medical concepts and uses, even though the 
translation of traditional medicine concepts in the 
Western medicine will often be problematic. 
In case of mechanistic 
pharmacological studies: 
How can the mechanism 
be evaluated for 
chemically complex 
preparations?  
Assess whether the assays are suitable for complex 
mixtures (including specificity of action of 
common constituents). 
Traceability of the source 
material is of critical 
relevance for the 
validation of published 
data.  
 
Details on the sourcing of the material are 
essential for future research and development (see 
below), also for those samples which are sourced 
from commercial suppliers.  
How can species, 
compounds been 
registered or are already 
with accession codes in 
data bases? 
All species (Rivera et al. 2014) or compounds or 
proteins need to be named using the existing 
international standards / accession codes in 
databases such as PubMed (chemical structure, 
substances, bioassay, Genes, …) 
https://www.ncbi.nlm.nih.gov. 
 
Medicinal plant name service 
(http://mpns.kew.org/mpns-portal/) or another 
17 
 
accepted taxonomic database. Note: 
Pharmacopoeias are not taxonomically validated 
sources. 
 
PDB (proteins, receptors, enzymes) 
https://www.rcsb.org. 
 
If it is a rare/little known plant from a wild 
collection, a photo from the mobile phone from all 
parts should be given in supporting material. Exact 
GIS data need to be provided for such materials. 
Concepts and 
methods 
What is the composition 
of the extract?  
Define botanical material used in sufficient 
scientific detail following international standards. 
Full authentication of the material. 
If possible, a simple metabolomic dataset based on 
1H-NMR (200 MHz or above), of the extract used 
or prepared according standardised extraction 
should be included. However, all editors are 
conscious that this may be difficult to achieve in a 
specific research setting and a range of chemical 
profiles can be considered. 
 
What analytical data are 
needed to define the 
material under study?  
Phytochemical profile if required by the journal, 
drug extract or drug solvent rations, description of 
the processing of the drug. 
Experimental design: 
Have the important 
methodological details 
been included? 
For in vivo studies, details such as randomization 
and blinding (whether or not performed), group 
size*, number of experiments**, vehicle used to 
dissolve drugs and vehicle effects, animal species 
(source, species, strain, sex, range of age and 
weight of animals), housing and husbandry, 




From the description, it must be clear that the 
study complies with the 3R of animal research 
(reduction, refinement, replacement), which, 
however, must not result in a loss of the statistical 
power of the experiment. 
What pharmacological 
methods are suitable and 
can be implemented / used 
in-house?  
Review of the approach and relevant literature on 
potential methods. 
 
What is the current 
methodological state-of-
the-art in the context of 
the specific research 
questions?  
Defining what would be the optimal approach 
from a pharmacological perspective (and see 
above providing a scientific justification for 
animal experiments).  
 
What are the most 
appropriate controls?  
Define positive and negative controls and use 
preferably standard drugs from clinics. 
The standard need to show significant activity in 
the assay and must have been validated and used 
over the years (e.g., penicillin G, amphoterin B, 
vincristine). This will also allow the calculation of 
the selectivity index, where applicable (e.g., 
cytotoxicity, anti-protozoal effects).  
What dose range is 
appropriate and of 
potential therapeutic 
relevance?  
Definition of dose range and explanation of the 
rationale provided for the selection of doses, route 
and frequency of drug administration. 
For compounds/extracts already used in humans, it 
is critical to have a dose–response curve in the 
experimental set up that includes the usual dose in 
humans. Differences in doses that normalize 
interspecies variation should be taken into 
account.*** 
It is not possible to define an exact upper cut-off 
dose, the dose range tested must still be 
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pharmacologically relevant. In many cases, a dose 
range of 100 – 200 mg/kg for in vivo studies of 
extracts (p.o. with the upper limit being much 
lower for i.p. and i.m. applications) and of 100 – 
200 g/ml should be assumed as being the upper 
limit for meaningful pharmacological studies. For 
pure compounds, a much lower dose range should 
be considered (ca. 50 mg/kg for in vivo studies of 
extracts (p.o.) and of 30 – 50 M for in vitro 
studies). The use of higher doses needs to be 
justified in detail.  
The evaluation of doses / concentrations that are 
much higher than what can be achieved in humans 
may be helpful in elucidating off-target effects and 
toxicities only, but it has no translational value 
from a therapeutic viewpoint. 
 
What dose causes 
toxicity?  
Selective is the best basis for assessing the 
relevance of the data. In addition, review the 
literature to check the maximal tolerated dose (or 
provide it experimentally) in order to define a 
therapeutic window.  
Statistical evaluation Are the statistical tools adequate for the 
experimental approach?  
Does the manuscript 
report a substantive body 
of phytopharmacological 
research? 
Assess – also based on the specific journal’s 
requirements – the breadth and detail of the data 
generated?  
Does the body of reported 
pharmacological effects 
cover a coherent area of 
activities, which allows a 
better understanding of 
Comparison of the experimental data, including an 










Are the resulting 
pharmacological data 
potentially linked to 
common (ubiquitous) 
compounds with known 
effects? 
Evaluation of the novelty of the information in the 
context of phytochemical/phytopharmacological 
data  
How specific is the 
pharmacological effect?  
In order to establish therapeutic benefits, 
selectivity data are essential [see also Baell and 
Walters (2014) and Hu and Bajorath, 2013)] 
which caution against spurious  bio-assay 
interferences especially in enzyme-based assays. 
In the case of anti-
microbial effects: Does 
the study follow the 
widely accepted standards 
for microbiological 
testing? 
Quality assessment of methods. Zones of 
inhibition alone are generally not adequate. 
Applying suitable 
statistics. 
Triplicates are the lowest number of data for 
statistics. Microsoft Excel is an inappropriate 
statistic software (in fact, not a statistical tool as 
such) and cannot be used as a statistic method in 
the experimental part. 
Anti-inflammatory effects. The term “inflammation” reflects a complex 
physiological situation that involves many cell 
types and signalling pathways. Thus, authors 
should use the term “anti-inflammatory” with 
caution and should consider the in vivo and/or in 
vitro model used to study “inflammation” very 
carefully. Similar considerations are needed when 
reporting other pharmacological interventions in 
complex physiological contexts.  
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Use of commercially 
available kits. 
The use of such kits must be validated, especially 
in the case of complex mixtures, to provide 
evidence for the specificity of the kit. 
Fluorescence detection can be particularly 
problematic. 
Antiproliferative/cytotoxic 




Show that extracts, compounds have selectivity 
and are not “anti-life” drugs. Ideally, a comparison 
of the effect between tumour and healthy cells (if 
available), especially when the effect is observed 
at high concentrations, should be provided. There 
should be some confidence that the tumour and 
normal cells are comparable in terms of growth 
rate, etc., to avoid artefacts. 
It is essential to clearly separate out anti-cancer 
research (in general in vivo) and research on cyto-
toxic pro-apoptotic effects. The relevance of a cell 
line must be justified. Also, make sure to 
distinguish between chemopreventive agents and 
anti-cancer agents, and use a proper reference. 
Compounds like platinum derivatives have poor 
activity in cellular assays, and their use leads to 
the wrong claim that cytotoxicity outperforms or is 
close to the one of a validated anticancer agent. 
In the case of antioxidant 
activity: what 
methodology has been 
used? 
Relevant antioxidant activities arise from 
pharmacologically-relevant in vivo or cell-based 
models. There is no evidence for therapeutic 
benefits on the basis of chemical anti-oxidant 
assays like the DPPH or FRAP and – in line with 
the policies of many journals, the journals do not 
accept them as a main pharmacological assay, but 
they remain useful as a chemical screening tool.  
Has the research question 
been answered / the 
An objective is not a hypothesis. Define your 
hypothesis or research question first and come 
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hypothesis evaluated? back to it in the Results and Discussion part. 
Assess outcomes in the context of previous 
knowledge.  
Have limitations or 
alternative interpretation 
of the data been 
considered? 
Highlight limitations and assessment of alternative 
interpretation. 
Does the research have 
clinical implications? 




What other important 
implications does this 
research have?  
Future research needs will, of course, depend on 
the context of the research, and while we do not 
want to provide detailed guidelines, any 
conclusion relating to future research needs must 
be specific and based on the data reported.  
 
 
* Group sizes should be equal by design, and any variation, due to experimental losses or 
violation of predetermined exclusion criteria, must be explained (see for details Curtis 
et al. Br J Pharmacol. 2015 Jul;172(14):3461-71) 
**The exact group size (n) for each experimental group/condition must be provided and the 
number of experiments (n) refers to independent values, not replicates [e.g., 3 samples 
each run in triplicate is n = 3 not n = 9 (see for details Curtis et al. Br J Pharmacol. 
2015 Jul;172(14):3461-71)] 
***see Nair AB, Jacob S. (2016) A simple practice guide for dose conversion between 





Figure 1: Scientific publishing as an iterative process of project development, data generation 
and assessment, evaluation and manuscript development. 
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